Eagle Asset Management Inc. Grows Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Eagle Asset Management Inc. raised its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMAFree Report) by 20.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,957 shares of the biotechnology company’s stock after purchasing an additional 4,367 shares during the quarter. Eagle Asset Management Inc.’s holdings in ADMA Biologics were worth $117,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Arizona State Retirement System increased its position in shares of ADMA Biologics by 4.9% during the fourth quarter. Arizona State Retirement System now owns 59,728 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 2,769 shares during the period. Swiss National Bank increased its position in shares of ADMA Biologics by 1.0% during the third quarter. Swiss National Bank now owns 439,800 shares of the biotechnology company’s stock valued at $1,574,000 after buying an additional 4,300 shares during the period. Victory Capital Management Inc. increased its position in shares of ADMA Biologics by 23.0% during the fourth quarter. Victory Capital Management Inc. now owns 29,192 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 5,465 shares during the period. Raymond James & Associates increased its position in shares of ADMA Biologics by 2.3% during the fourth quarter. Raymond James & Associates now owns 249,296 shares of the biotechnology company’s stock valued at $1,127,000 after buying an additional 5,657 shares during the period. Finally, Mesirow Financial Investment Management Inc. increased its position in shares of ADMA Biologics by 8.2% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 78,605 shares of the biotechnology company’s stock valued at $376,000 after buying an additional 5,928 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Raymond James upped their price target on ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a research report on Friday, May 10th. Mizuho upped their price objective on shares of ADMA Biologics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. HC Wainwright upped their price objective on shares of ADMA Biologics from $7.50 to $10.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. Finally, Cantor Fitzgerald upped their price objective on shares of ADMA Biologics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, May 10th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $10.50.

Get Our Latest Stock Report on ADMA

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 407,000 shares of the stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $6.21, for a total transaction of $2,527,470.00. Following the transaction, the director now directly owns 3,208,671 shares in the company, valued at $19,925,846.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 639,895 shares of company stock worth $3,927,169 over the last ninety days. Insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Up 4.0 %

ADMA stock opened at $10.49 on Thursday. ADMA Biologics, Inc. has a 1-year low of $3.06 and a 1-year high of $10.54. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91. The company’s 50 day moving average is $7.59 and its 200 day moving average is $5.88. The stock has a market cap of $2.43 billion, a price-to-earnings ratio of -524.50 and a beta of 0.48.

ADMA Biologics (NASDAQ:ADMAGet Free Report) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.03. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The business had revenue of $81.90 million for the quarter, compared to analysts’ expectations of $77.28 million. During the same period last year, the business earned ($0.03) earnings per share. The business’s quarterly revenue was up 43.9% on a year-over-year basis. Sell-side analysts predict that ADMA Biologics, Inc. will post 0.35 EPS for the current fiscal year.

About ADMA Biologics

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Articles

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMAFree Report).

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.